CD8A and neoplasm: The results indicated that PD1 inhibitor activated the spleen to produce more T cells, and that the E0771M-AP NPs combined with the PD1 inhibitor could recruit more CD8+ T cells into the tumor, which slightly decreased the percentage of CD8+ T cells in the blood (Fig. 6C).